QIAGEN has acquired a novel diagnostic technology through its purchase of Australian company Cellestis.
QIAGEN has paid US$355 million in cash and gained exclusive rights to QuantiFERON technology, which offers quicker and more sensitive disease detection than is possible with other diagnostic methods.
QuantiFERON-TB Gold In-Tube (QFT) is approved as a test for latent tuberculosis (TB) and QuantiFERON-CMV is available for the monitoring of disease risk from cytomegalovirus (CMV).
The platform technology can provide information on diseases earlier than is possible with DNA- or RNA-based molecular testing. It is also able to detect latent infections, where pathogens are present in such low amounts that they would not otherwise be detectable.
“The power of QuantiFERON can help save lives by enabling medical treatment through earlier, deeper and much more sensitive disease detection than previously possible,” said Peer Schatz, CEO of QIAGEN.
“Cellestis has developed a technology that is highly complementary to our portfolio and which we expect to migrate onto our QIAsymphony, QIAensemble and our point of need platforms, thereby adding a new, unique assay menu to these QIAGEN platforms.”
Cellestis CEO Anthony Radford added: “We believe QIAGEN as an industry-leading company provides the best strategic fit in terms of capabilities and resources. As part of QIAGEN, we will be able to accelerate our growth much faster than as a stand-alone company and offer even greater benefits to patients and healthcare providers.”
Netherlands-based QIAGEN has developed and markets more than 500 sample and assay products.